Thanks, Daniel. Good morning, everyone, and thank you for joining us today. Throughout the third quarter of 2021, we executed several initiatives to further build momentum on the accomplishments we garnered in the previous quarter, including our merger with Obalon and listing on the NASDAQ. I am also pleased to report that we continue to strengthen our market position as demonstrated by our growing revenues for the first nine months in 2021 of $10.5 million, representing a 29% increase from the same period last year. Before I discuss in detail the work we've done to maximize the value of our product portfolio, I'd like to provide a brief synopsis of the massive market opportunity to ReShape. Studies show that 73% of American adults are overweight or obese, with about 50% of that population seeking to lose weight every year. To capitalize on this multibillion-dollar opportunity in the U.S. market by 2025, we made the informed and strategic decision to allocate our resources towards the debut of the Company's first and largest mass media, multi-platform advertising campaign for our lead product, the LAP-BAND, which has specific weight loss indications approved by the FDA and is covered by most insurance plans. Available across national television channels and major print publications, our goal is to effectively communicate the important benefits of the LAP-BAND directly to our targeted audience. We want to ensure that our product has high visibility in the marketplace for anyone seriously considering weight loss options. It is essential for the Company to promote the differentiators of our product, including its safety and efficacy profiles as well as the ability of this technology to be adjusted for individual needs and the procedure being available in outpatient surgery centers, with most patients going home the same day. Confirmed through recent test marketing programs and corroborated with historical impact of patient marketing programs for the LAP-BAND, we are highly encouraged by the substantial consumer engagement and revenue potential this campaign presents. To capture and retain patients in our ecosystem of weight loss solutions, we are also promoting ReShape Care, our reimbursed virtual weight management program led by physicians as a nonsurgical-based weight loss program as well as an after care support model for the bariatric surgeries that are available. Regarding product demand and interest, a Harris Poll research study reported that 61% of American adults experienced undesired weight changes during the pandemic, with 42% claiming they gained more weight than intended an average of 29 pounds. As the go-to company for physician-led weight loss products, we were approached by a number of health care professionals to help them adapt their practices for patients seeking weight last treatment during the pandemic. We responded in two ways: by citing the functionality of our LAP-BAND in outpatient surgery settings; and introducing ReShape Care, our physician-managed, reimbursed virtual health coaching program for their patients. Along with building a proprietary ecosystem of weight loss solutions that makes us unique, we've created a hub for patients seeking help across the continuum of care, a strategy that also supports long-term patient and customer retention. Our decision to launch ReShape Care was another way of addressing physician and consumer demand for accessible, customizable and engaging online medical solutions. Our entry into the virtual health care delivery space allows us to tap into a market that is expected to reach $95 billion by 2026. Given the strong potential of the seamless physician-prescribed digital health offering, we anticipate to generate increasing revenue for this program in the fourth quarter of 2021 and into 2022. In July 2021, we launched ReShape Marketplace as an extension of ReShape Care, offering consumers an e-commerce option to access the collection of competitively priced and practical weight loss and wellness solutions and products covering the vital areas of nutrition, exercise, sleep and stress. To further the promise of ReShape Marketplace, we recently announced the addition of a new product supplement line comprised of bariatric multivitamins and supplements by ProCare Health. During the past few quarters, we made mention of proactively revising and enhancing our manufacturing and commercial efforts to maximize profitability and ensure operational efficiencies within our business. To that effect, we are very happy to welcome Al Diaz, our newly appointed Vice President of Operations and Research and Development to ReShape. Al is an experienced and successful industry veteran in health care operations, who most recently served as EVP of Operations at ClearFlow, Inc., where he oversaw the broad strategic direction of all manufacturing and material management operations. Emerging from the pandemic, we also added key field personnel to support and engage practices in preparation for the anticipated patient flow from our patient direct marketing campaign. With respect to augmenting our product line and subsequent to the completion of our merger with Obalon, we continue to explore the option of adding the Obalon balloon technology to our commercial offering. The FDA-approved gastric balloon system offers a nonsurgical, minimally invasive approach to helping patients maintain a controlled diet, thereby making weight loss more achievable. Now I'd like to turn to our product pipeline. Once we receive necessary approvals from the study sites, we will be ready to resume our EU-based clinical trials for the ReShape Vest, a laparoscopic implantable technology designed to support and enhance the patient's weight loss journey. Clinical investigation of the product will continue to be conducted in different locations of Europe, and we have continued to work with those clinicians to remain in a state preparedness for the reopening of their medical facility access. With the assistance of a grant from the NIH, we completed and met the necessary endpoints for the preclinical study of the ReShape Diabetes Bloc-Stim Neuromodulation technology. This platform utilizes proprietary simultaneous nerve stimulation and blocking to adjust insulin production and potentially treat type 2 diabetes. We remain committed to evaluating the potential of this platform through additional nondilutive graft funding. We have developed strategies and tactics that will build the structural framework for sustainable growth in the medium to long term. Additionally, continuing from the medical conference taking place this month in Düsseldorf, we will continue to pursue M&A opportunities that align with our current portfolio and present sound revenue-generating potential. In summary, we are confident that our enhanced commercial strategy will improve our revenue and profitability position. We will continue to implement programs that drive demand for our products while fostering a positive future for ReShape. I look forward to providing further updates on our progress in the quarters to come. I will now turn the presentation over to Tom for a review of our financial performance. Tom?